Papaioannides Dimitrios, Fotinou Marianthi, Korantzopoulos Panagiotis, Latsi Panagiota, Sinapidis Demetrios, Akritidis Nikolaos, Orphanidou Dora
Department of Medicine, Arta Hospital, Arta, Greece.
Med Sci Monit. 2004 Jan;10(1):CS5-7.
Recombinant interferon-alpha (IFN-alpha ) is widely used for the treatment of chronic hepatitis C. Pulmonary side effects of IFN-alpha therapy seem to be rare. So far, only a few cases of sarcoidosis in association with IFN-alpha treatment of chronic hepatitis C have been
A 52-year-old woman with chronic hepatitis C developed sarcoidosis during treatment with IFN-alpha. Diagnosis of sarcoidosis was based on chest imaging studies, the increased serum angiotensin converting enzyme levels, and the histology of a biopsied cervical lymph node. Spontaneous remission was observed following IFN-alpha withdrawal.
Use of recombinant IFN-alpha in patients with chronic hepatitis C may trigger or contribute to the development of sarcoidosis in susceptible individuals. Patients should be monitored during and following IFN-alpha therapy for the occurrence of manifestations suggesting sarcoidosis.
重组干扰素-α（IFN-α）广泛用于治疗慢性丙型肝炎。IFN-α治疗的肺部副作用似乎罕见。迄今为止，仅有少数几例与IFN-α治疗慢性丙型肝炎相关的结节病病例报道。
一名52岁的慢性丙型肝炎女性在接受IFN-α治疗期间发生结节病。结节病的诊断基于胸部影像学检查、血清血管紧张素转换酶水平升高以及活检的颈部淋巴结组织学检查。停用IFN-α后观察到自发缓解。
在慢性丙型肝炎患者中使用重组IFN-α可能会触发或促使易感个体发生结节病。在IFN-α治疗期间及之后，应对患者进行监测，以观察是否出现提示结节病的表现。
Zotero 插件